VAM
LSB

Valliance Asset Management’s LakeShore Biopharma LSB Stock Holding History

Valliance Asset Management’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-160,718
Closed -$821K – 12
2023
Q4 		$821K Hold
160,718
– – 29.03% 2
2023
Q3 		$1.29M Hold
160,718
– – 4.68% 7
2023
Q2 		$2.22M Hold
160,718
– – 35.42% 2
2023
Q1 		$2.57M Buy
+160,718
New +$8.14M 4.59% 5

Other funds holding LSB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
SCM
Superstring Capital Management New York $158M AUM 418.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAM
Pinpoint Asset Management Hong Kong $576M AUM 43.65% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Valliance Asset Management's LSB Position: Q1 2024 in Review

Valliance Asset Management sold out of LakeShore Biopharma (LSB) in Q1 2024, closing a stake of 160,718 shares — an estimated $821K sold.

Valliance Asset Management first reported a position in LSB in Q1 2023 and held it in 4 quarters. The position peaked at $2.57M in Q1 2023. 9 funds tracked by Wall St. Rank hold LSB as of Q1 2024.

  • Valliance Asset Management reported no remaining LakeShore Biopharma position as of Q1 2024 after selling out during the quarter.
  • Valliance Asset Management sold 160,718 LakeShore Biopharma shares in Q1 2024, an estimated $821K.
  • Valliance Asset Management first reported a position in LakeShore Biopharma in Q1 2023 and held it in 4 quarters.
  • Valliance Asset Management's LakeShore Biopharma position peaked at $2.57M in Q1 2023.
  • 9 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q1 2024.

Based on Valliance Asset Management's 13F filing for Q1 2024, filed 7 May 2024.